Treating Metastatic NSCLC: Choosing the Best Treatment for Optimal Outcomes : Episode 1

Sarah’s Journey With ALK+ Metastatic NSCLC

December 23, 2024

Opinion

Video

A 55-year-old mom and high school teacher who received lorlatinib for ALK+ NSCLC with brain metastases.

Now Viewing

EP: 1.Sarah’s Journey With ALK+ Metastatic NSCLC

EP: 2.Patient Education: Preparing Patients for ALK Inhibitor Treatment

EP: 3.Strategies for Managing Neurotoxic AEs With Lorlatinib

EP: 4.Lorlatinib AE Management: Weight Gain and GI Issues

EP: 5.Multidisciplinary Approach to AE Management With Lorlatinib

EP: 6.Real-World Management of AEs with ALK Inhibitors

EP: 7.Eleanor’s Journey With KRAS+ Metastatic NSCLC

EP: 8.Educating Patients About AEs Associated With KRAS-Targeted Therapies in NSCLC

EP: 9.Managing AEs Associated With Adagrasib for NSCLC

EP: 10.Goals of Care: in mNSCLC Balancing QOL and Treatment Maintenance

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!

Latest Conference Coverage

Safety Management With Amivantamab Plus Lazertinib in NSCLC

Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

Adverse Events of Menin Inhibitors in AML: What Nurses Should Know

Ivonescimab/Chemo Ups PFS After Third-Generation TKI in EGFR+ NSCLC

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777